PHARMACODYNAMIC EFFECTS OF ADJUNCTIVE CLOPIDOGREL THERAPY IN PATIENTS WITH ATHEROSCLEROTIC DISEASE ON DUAL PATHWAY INHIBITION WITH ASPIRIN AND LOW-DOSE RIVAROXABAN

MLA

Martin Zenni, et al. “Pharmacodynamic Effects of Adjunctive Clopidogrel Therapy in Patients with Atherosclerotic Disease on Dual Pathway Inhibition with Aspirin and Low-Dose Rivaroxaban.” Journal of the American College of Cardiology, vol. 77, May 2021, p. 1187. EBSCOhost, https://doi.org/10.1016/s0735-1097(21)02546-8.

APA

Martin Zenni, Siva Suryadevara, Fabiana Rollini, Dominick J. Angiolillo, Naji Maaliki, Latonya F. Been, Sida Jia, Patrick Abou Jaoude, Andrea Rivas, Xuan Zhou, Andres Pineda Maldonado, Francesco Franchi, Lisa K. Jennings, Daniel Soffer, Theodore A. Bass, & Chang Hoon Lee. (2021). Pharmacodynamic Effects of Adjunctive Clopidogrel Therapy in Patients with Atherosclerotic Disease on Dual Pathway Inhibition with Aspirin and Low-Dose Rivaroxaban. Journal of the American College of Cardiology, 77, 1187. https://doi.org/10.1016/s0735-1097(21)02546-8

Chicago

Martin Zenni, Siva Suryadevara, Fabiana Rollini, Dominick J. Angiolillo, Naji Maaliki, Latonya F. Been, Sida Jia, et al. 2021. “Pharmacodynamic Effects of Adjunctive Clopidogrel Therapy in Patients with Atherosclerotic Disease on Dual Pathway Inhibition with Aspirin and Low-Dose Rivaroxaban.” Journal of the American College of Cardiology 77 (May): 1187. doi:10.1016/s0735-1097(21)02546-8.